

Exhibit 1
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of US dollars)

	As of December 31, 2013 US\$ (Note 1)	As of September 30, 2014 US\$ (unaudited)
ASSETS		
Current assets:		
Cash and cash equivalents (Note 2)	385,224	197,384
Restricted cash (Note 3)	759	8,942
Short-term investments (Note 2)	847,041	775,506
Accounts receivable, net	220,228	192,211
Inventories	138,808	172,036
Value added tax receivables	10,225	13,660
Other receivables	21,512	22,538
Prepayments and deposits	14,310	19,766
Deferred tax assets, net	9,585	11,646
Total current assets	1,647,692	1,413,689
Restricted cash, non-current (Note 3)	17,453	10,060
Other assets	10,755	10,168
Accounts receivables, net, non-current	1,389	2,815
Advances for purchase of plant and equipment	18,919	19,843
Property, plant and equipment, net	324,710	370,684
Land use rights, net	59,463	58,748
Intangible assets, net	181,077	180,428
Goodwill	242,476	253,974
Total assets	2,503,934	2,320,409
LIABILITIES AND EQUITY		
Current liabilities:		
Short-term bank loans	260,000	58,750
Notes payable	10,945	9,832
Accounts payable	93,673	97,583
Advances from customers	28,240	33,137
Salaries payable	91,220	75,308
Other payables and current liabilities	118,951	125,984
Purchase consideration payable	20,457	23,654
Income taxes payable	20,721	16,604
Other taxes payable	12,832	5,992
Total current liabilities	657,039	446,844
Long-term bank loans	215,703	204,219
Other long-term liabilities	7,222	9,841
Deferred tax liabilities, net	45,812	55,027
Total liabilities	925,776	715,931
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	521,617	449,345
Retained earnings	865,676	948,264
Accumulated other comprehensive income	150,432	135,052
Treasury stock at cost	(18,792)	-
Total shareholders' equity	1,518,948	1,532,676
Non-controlling interests	59,210	71,802
Total equity	1,578,158	1,604,478
Total liabilities and equity	2,503,934	2,320,409

- (1) Financial information is extracted from the audited financial statements included in the Company's 2013 annual report on Form 20-F.
- (2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of \$241,500 and \$189,000 as of December 31, 2013 and September 30, 2014, respectively in relation to the drawings of certain bank loans.
- (3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.

Exhibit 2
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of US dollars, except share and per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2013	2014	2013	2014
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Net revenues				
- <i>China</i>	132,007	155,699	390,754	423,996
- <i>International</i>	164,311	168,937	454,818	499,863
Net revenues	296,318	324,636	845,572	923,859
Cost of revenues	(131,180)	(141,799)	(364,886)	(405,787)
Gross profit	165,138	182,837	480,686	518,072
Selling expenses	(57,499)	(65,800)	(159,215)	(184,067)
General and administrative expenses	(25,530)	(39,293)	(78,743)	(96,684)
Research and development expenses	(31,573)	(34,346)	(86,474)	(98,213)
Income from operations	50,536	43,398	156,254	139,108
Other income, net	333	631	832	2,225
Interest income	10,034	9,530	26,261	27,987
Interest expense	(1,742)	(1,462)	(4,185)	(5,148)
Income before income taxes and non-controlling interests	59,161	52,097	179,162	164,172
Income tax provision	(27,935)	(4,729)	(25,744)	(18,677)
Net income	31,226	47,368	153,418	145,495
Less: Net income attributable to non-controlling interests	(1,162)	(1,325)	(3,880)	(4,196)
Net income attributable to the Company	30,064	46,043	149,538	141,299
Basic earnings per share	0.25	0.39	1.26	1.21
Diluted earnings per share	0.25	0.39	1.24	1.19
Shares used in the computation of:				
Basic earnings per share	119,142,051	117,106,169	118,616,515	116,979,193
Diluted earnings per share	121,162,145	118,231,031	120,945,344	118,315,564

Exhibit 3
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of US dollars)

	Three months ended September 30,		Nine months ended September 30,	
	2013	2014	2013	2014
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Cash flow from operating activities:				
Net income	31,226	47,368	153,418	145,495
Adjustments to reconcile net income to net cash provided by operating activities	18,775	22,969	51,104	71,666
Changes in assets and liabilities, net of effects of acquisitions	17,096	15,187	(18,800)	(27,372)
Net cash provided by operating activities	67,097	85,524	185,722	189,789
Cash flow from investing activities:				
Acquisition cost of subsidiaries, net of cash received	(87,533)	(852)	(105,018)	(9,067)
Capital expenditures	(26,939)	(28,057)	(67,179)	(79,108)
(Increase) decrease in restricted cash	(18,304)	724	2,960	(790)
Proceeds from sale of short-term investments	187,471	184,247	591,808	800,762
Increase in short-term investments and changes in other investing activities	(244,626)	(407,911)	(794,145)	(749,649)
Net cash used in investing activities	(189,931)	(251,849)	(371,574)	(37,852)
Cash flow from financing activities:				
Repayment of bank loans	-	-	(35,000)	(210,000)
Proceeds from bank loans	120,000	-	215,000	-
Dividend paid	-	-	(59,070)	(58,711)
Proceeds from exercise of options	6,748	1,731	15,600	2,745
Repurchase of ordinary American depositary shares	-	-	-	(68,080)
Cash paid to acquire a non-controlling interest	-	-	-	(4,731)
Cash contribution from a non-controlling interest	-	416	-	655
Net cash provided by (used in) financing activities	126,748	2,147	136,530	(338,122)
Net increase (decrease) in cash and cash equivalents	3,914	(164,178)	(49,322)	(186,185)
Cash and cash equivalents, beginning of period	195,373	362,311	247,859	385,224
Effect of exchange rate changes on cash and cash equivalents	731	(749)	1,481	(1,655)
Cash and cash equivalents, end of period	200,018	197,384	200,018	197,384

Exhibit 4
MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES

(In thousands of US dollars, except share and per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2013	2014	2013	2014
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	US\$	US\$	US\$	US\$
Non-GAAP net income attributable to the Company	57,412	56,157	190,220	168,430
<i>Non-GAAP net margin</i>	19.4%	17.3%	22.5%	18.2%
Amortization of acquired intangible assets	(3,948)	(3,499)	(9,752)	(10,384)
Withholding tax for intra-group fund transfer	(20,804)	-	(20,804)	-
Deferred tax impact related to acquired intangible assets	353	662	768	1,881
Dispute related legal fees, net of tax impact	-	(2,340)	-	(2,340)
Share-based compensation	(2,949)	(4,937)	(10,894)	(16,288)
GAAP net income attributable to the Company	30,064	46,043	149,538	141,299
<i>GAAP net margin</i>	10.1%	14.2%	17.7%	15.3%
Non-GAAP basic earnings per share	0.48	0.48	1.60	1.44
Non-GAAP diluted earnings per share	0.47	0.47	1.57	1.42
GAAP basic earnings per share	0.25	0.39	1.26	1.21
GAAP diluted earnings per share	0.25	0.39	1.24	1.19
Shares used in computation of:				
Basic earnings per share	119,142,051	117,106,169	118,616,515	116,979,193
Diluted earnings per share	121,162,145	118,231,031	120,945,344	118,315,564
Non-GAAP operating income	57,433	54,434	176,900	168,380
<i>Non-GAAP operating margin</i>	19.4%	16.8%	20.9%	18.2%
Amortization of acquired intangible assets	(3,948)	(3,499)	(9,752)	(10,384)
Dispute related legal fees	-	(2,600)	-	(2,600)
Share-based compensation	(2,949)	(4,937)	(10,894)	(16,288)
GAAP operating income	50,536	43,398	156,254	139,108
<i>GAAP operating margin</i>	17.1%	13.4%	18.5%	15.1%
Non-GAAP gross profit	167,222	185,119	486,641	524,657
<i>Non-GAAP gross margin</i>	56.4%	57.0%	57.6%	56.8%
Amortization of acquired intangible assets	(1,888)	(1,808)	(5,415)	(5,676)
Share-based compensation	(196)	(474)	(540)	(909)
GAAP gross profit	165,138	182,837	480,686	518,072
<i>GAAP gross margin</i>	55.7%	56.3%	56.8%	56.1%
Non-GAAP selling expenses	(54,182)	(61,486)	(151,279)	(174,245)
<i>Non-GAAP as % of total net revenues</i>	18.3%	18.9%	17.9%	18.9%
Amortization of acquired intangible assets	(2,060)	(1,691)	(4,337)	(4,708)
Share-based compensation	(1,257)	(2,623)	(3,599)	(5,114)
GAAP selling expenses	(57,499)	(65,800)	(159,215)	(184,067)
<i>GAAP as % of total net revenues</i>	19.4%	20.3%	18.8%	19.9%
Non-GAAP general and administrative expenses	(25,007)	(36,061)	(75,188)	(87,467)
<i>Non-GAAP as % of total net revenues</i>	8.4%	11.1%	8.9%	9.5%
Dispute related legal fees	-	(2,600)	-	(2,600)
Share-based compensation	(523)	(632)	(3,555)	(6,617)
GAAP general and administrative expenses	(25,530)	(39,293)	(78,743)	(96,684)
<i>GAAP as % of total net revenues</i>	8.6%	12.1%	9.3%	10.5%
Non-GAAP research and development expenses	(30,600)	(33,138)	(83,274)	(94,565)
<i>Non-GAAP as % of total net revenues</i>	10.3%	10.2%	9.8%	10.2%
Share-based compensation	(973)	(1,208)	(3,200)	(3,648)
GAAP research and development expenses	(31,573)	(34,346)	(86,474)	(98,213)
<i>GAAP as % of total net revenues</i>	10.7%	10.6%	10.2%	10.6%

Exhibit 5**MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION****(In thousands of US dollars)**

	Three months ended September 30,		Nine months ended September 30,	
	2013	2014	2013	2014
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
GAAP net income attributable to the Company	30,064	46,043	149,538	141,299
Interest income	(10,034)	(9,530)	(26,261)	(27,987)
Interest expense	1,742	1,462	4,185	5,148
Income tax provision	27,935	4,729	25,744	18,677
Earnings before interest and taxes ("EBIT")	49,707	42,704	153,206	137,137
Depreciation	8,804	9,070	24,514	26,402
Amortization	6,152	5,743	15,649	16,889
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	<u>64,663</u>	<u>57,517</u>	<u>193,369</u>	<u>180,428</u>